Verekitug for Nasal Polyps
(VIBRANT Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests a new injectable medication, verekitug (UPB-101), for people with chronic rhinosinusitis and nasal polyps who are already using nasal sprays. The goal is to see if it can shrink the polyps and improve symptoms.
Will I have to stop taking my current medications?
The trial does not specify if you need to stop taking your current medications, but you must have stable treatment for nasal polyps for at least 30 days before starting the trial and continue using a nasal spray like mometasone furoate during the trial.
Who Is on the Research Team?
Kiran Patel, MD
Principal Investigator
Upstream Bio
Are You a Good Fit for This Trial?
This trial is for adults aged 18-75 with chronic rhinosinusitis and nasal polyps who need surgery, have ongoing symptoms like runny nose or loss of smell, and have had a past flare-up treated with steroids. They must not be able to use systemic corticosteroids, agree to the study's consent form, and have been on stable treatment for at least 30 days.Inclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive verekitug (UPB-101) or placebo subcutaneously every 12 weeks for 24 weeks
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Verekitug (UPB-101)
Find a Clinic Near You
Who Is Running the Clinical Trial?
Upstream Bio Inc.
Lead Sponsor